-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Johnson and Johnson have reached an agreement with Swedish biotech company Alligator Bioscience on the ADC-1013 project, and Janssen, a subsidiary of Johnson and Johnson, will receive the right to develop and sell ADC-1013, a CD40-targeted antibody in Alligator. Alligator Bioscience is a biotechnology company based on innovative research focused on cancer immunotherapy based on new antibody drugs. ADC-1013 activates T lymphocytes to attack tumor cells for cancer treatment.
agreement provides that Allitor will receive an unannoled advance of an amount, plus mileage funds, for a transaction value of $700 million. The ADC-1013-related trial project is currently in Clinical Phase I research and Jansen will be responsible for all subsequent clinical trials and post-sales of the project once the ongoing dose increment trial is completed.
In cancer treatment, people have developed chemotherapy, radiotherapy and other methods, these treatments are either ineffective, can not inhibit the crazy growth of tumor cells, or in the killing of tumor cells at the same time make the patient's own cell damage. With people's understanding of the immune system, the field of biomedical research has set off a wave of research on tumor immunotherapy. Pharmaceutical giants are getting involved, and the wave of mergers and acquisitions related to oncology immunotherapy has been booming, the most active module in the life sciences.
in the field of tumor immunotherapy, Johnson and Johnson focused on improving the patient's immune response to tumors through related drugs, rather than using drugs to kill tumor cells directly. Johnson and Johnson has been a frequent mover in cancer research and development, working with biotech companies such as Aduro to develop anti-cancer drugs for a variety of cancers. Just this week, Johnson and Johnson licensed a technology called Poseida Therapeutics that could be used in another hot field of tumor immunotherapy, immuno-oncology-embedded antigen-subject therapy (CAR-T). At the same time, other pharmaceutical giants are also competing in this arena, hundreds of meishu Shiguibao and Mercado already have related drugs on the market, AstraZeneta, Roche, Pfizer / Mercado related drugs are also in the late stage of research and development.
Johnson and Johnson's efforts to establish a series of innovation centers around the world in the field of biomedicine, and to establish partnerships with academic centers and innovative companies, the agreement between Jassen and Allitor was brokered by Johnson and Johnson London Center. Peter Lebowitz, Head of Oncology Research and Development at Jansen, said Jansen's tumor immune portfolio is expanding, and the addition of ADC-1013 has undoubtedly largely complemented its cancer drug development pipeline. We were impressed by the prospect of the application of Alligator antibodies, and we are pleased to continue this research and hope to eventually bring it to patients. (New Kangjie)